Get Started

GLPG

Galapagos (GLPG)

Galapagos

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:EU:GLPG

<< Previous 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Next >>

Date	Time	Source	Headline	Symbol	Company
06/20/2017	4:01PM	GlobeNewswire Inc.	Galapagos increases share capital through warrant exercises	EU:GLPG	Galapagos
06/20/2017	4:01PM	GlobeNewswire Inc.	Galapagos increases share capital through warrant exercises	EU:GLPG	Galapagos
06/20/2017	1:32AM	GlobeNewswire Inc.	Galapagos' R&D Update 2017: rapidly advancing our product candidates	EU:GLPG	Galapagos
06/20/2017	1:32AM	GlobeNewswire Inc.	Galapagos' R&D Update 2017: rapidly advancing our product candidates	EU:GLPG	Galapagos
05/17/2017	4:01PM	GlobeNewswire Inc.	Galapagos creates new warrant plan	EU:GLPG	Galapagos
05/17/2017	4:01PM	GlobeNewswire Inc.	Galapagos creates new warrant plan	EU:GLPG	Galapagos
05/15/2017	4:02PM	GlobeNewswire Inc.	Seven abstracts on filgotinib accepted by EULAR 2017	EU:GLPG	Galapagos
05/15/2017	4:02PM	GlobeNewswire Inc.	Seven abstracts on filgotinib accepted by EULAR 2017	EU:GLPG	Galapagos
05/07/2017	10:36AM	GlobeNewswire Inc.	Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017	EU:GLPG	Galapagos
05/07/2017	10:36AM	GlobeNewswire Inc.	Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017	EU:GLPG	Galapagos
04/29/2017	1:31AM	GlobeNewswire Inc.	Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI	EU:GLPG	Galapagos
04/29/2017	1:31AM	GlobeNewswire Inc.	Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI	EU:GLPG	Galapagos
04/27/2017	4:01PM	GlobeNewswire Inc.	Galapagos reports first quarter 2017 results	EU:GLPG	Galapagos
04/27/2017	4:01PM	GlobeNewswire Inc.	Galapagos reports first quarter 2017 results	EU:GLPG	Galapagos
04/25/2017	4:01PM	GlobeNewswire Inc.	Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus	EU:GLPG	Galapagos
04/25/2017	4:01PM	GlobeNewswire Inc.	Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus	EU:GLPG	Galapagos
04/21/2017	4:03PM	GlobeNewswire Inc.	Galapagos announces capital increase	EU:GLPG	Galapagos
04/21/2017	4:03PM	GlobeNewswire Inc.	Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million	EU:GLPG	Galapagos
04/21/2017	4:03PM	GlobeNewswire Inc.	Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million	EU:GLPG	Galapagos
04/21/2017	4:03PM	GlobeNewswire Inc.	Galapagos announces capital increase	EU:GLPG	Galapagos
04/17/2017	10:11PM	GlobeNewswire Inc.	Galapagos raises $338 million gross proceeds in a U.S. public offering	EU:GLPG	Galapagos
04/17/2017	10:11PM	GlobeNewswire Inc.	Galapagos raises $338 million gross proceeds in a U.S. public offering	EU:GLPG	Galapagos
04/17/2017	4:11PM	GlobeNewswire Inc.	Galapagos announces launch of proposed public offering	EU:GLPG	Galapagos
04/17/2017	4:11PM	GlobeNewswire Inc.	Galapagos announces launch of proposed public offering	EU:GLPG	Galapagos
04/06/2017	4:01PM	GlobeNewswire Inc.	Galapagos increases share capital through warrant exercises	EU:GLPG	Galapagos
04/06/2017	4:01PM	GlobeNewswire Inc.	Galapagos increases share capital through warrant exercises	EU:GLPG	Galapagos
04/05/2017	4:01PM	GlobeNewswire Inc.	Galapagos doses first psoriatic arthritis patient with filgotinib	EU:GLPG	Galapagos
04/05/2017	4:01PM	GlobeNewswire Inc.	Galapagos doses first psoriatic arthritis patient with filgotinib	EU:GLPG	Galapagos
04/04/2017	1:31AM	GlobeNewswire Inc.	Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib	EU:GLPG	Galapagos
04/04/2017	1:31AM	GlobeNewswire Inc.	Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib	EU:GLPG	Galapagos